Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Astellas-Vical’s CMV Vaccine Disappoints in PII for Kidney Transplant Patients
Astellas Pharma said on September 20 that ASP0113, its investigational cytomegalovirus (CMV) vaccine being developed with US partner Vical, failed to meet the primary endpoint in a multinational PII study covering kidney transplant patients. The randomized, double-blind, placebo-controlled study looked…
To read the full story
Related Article
- Astellas/Vical’s CMV Vaccine Flops in Global PIII
January 23, 2018
- Astellas Begins Global PIII Study of Cytomegalovirus Vaccine
June 27, 2013
- Astellas Licenses Transplant Viremia Prevention Vaccine from Vical
August 1, 2011
BUSINESS
- Chugai Forms Strategic Investment Unit to Deepen Innovation Push; Record Japan Filings Eyed
July 27, 2026
- Chugai Notches Strong H1 Growth on Key Products, Roche Exports
July 27, 2026
- Meiji’s Hiyasta Hits PIII Goal in Advanced Melanoma
July 27, 2026
- China First to Approve Takeda’s Oveporexton for Narcolepsy
July 24, 2026
- FRONTEO Expects First US User of KIBIT AI Engine This Year: CEO
July 24, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…